Contrasting Viridian Therapeutics (NASDAQ:VRDN) & MDxHealth (NASDAQ:MDXH)

Viridian Therapeutics (NASDAQ:VRDN) and MDxHealth (NASDAQ:MDXH) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability and analyst recommendations.

Profitability

This table compares Viridian Therapeutics and MDxHealth’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Viridian Therapeutics	-62,437.76%	-100.07%	-55.40%
MDxHealth	-78.05%	-217.38%	-36.27%

Valuation & Earnings

This table compares Viridian Therapeutics and MDxHealth’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viridian Therapeutics	$1.77 million	394.26	-$129.87 million	($5.10)	-3.13
MDxHealth	$63.69 million	1.34	-$44.04 million	($1.85)	-1.69

MDxHealth has higher revenue and earnings than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Viridian Therapeutics and MDxHealth, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viridian Therapeutics	0	0	14	0	3.00
MDxHealth	0	0	3	0	3.00

Viridian Therapeutics presently has a consensus price target of $40.29, indicating a potential upside of 152.10%. MDxHealth has a consensus price target of $6.67, indicating a potential upside of 113.68%. Given Viridian Therapeutics’ higher probable upside, equities analysts plainly believe Viridian Therapeutics is more favorable than MDxHealth.

Risk & Volatility

Viridian Therapeutics has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500. Comparatively, MDxHealth has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500.

Insider & Institutional Ownership

20.2% of MDxHealth shares are owned by institutional investors. 1.4% of Viridian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

MDxHealth beats Viridian Therapeutics on 7 of the 13 factors compared between the two stocks.

About Viridian Therapeutics

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-002 and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-004, a discovery-stage therapeutic antibody program for rare disease; and VRDN-005 and VRDN-006, a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. is headquartered in Waltham, Massachusetts.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.